Scinai Immunotherapeutics Ltd. stocks have been trading up by 7.76 percent amid heightened optimism from its latest biotech developments.
Click Here for a Millionaire's POV on Trading SCNI
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Nasdaq has confirmed that Scinai Immunotherapeutics is back in full compliance with the $1.00 minimum bid rule, removing the immediate delisting threat.
- Compliance was regained after 19 straight trading days with the share price holding above $1.00, signaling firmer price support in SCNI.
- The company continues to advance its NanoAb immunology programs, which remain the core scientific driver behind SCNI.
- Alongside the pipeline, management is pushing to grow Scinai’s contract development and manufacturing (CDMO) operations as an additional revenue engine.
Live Update At 15:04:12 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 7.76%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
SCNI has been trading like a classic small-cap biotech battleground. Over the past several sessions, Scinai Immunotherapeutics has swung from a recent high near $2.33 in early premarket to a close around $1.25 on 2026/10/13. That’s a sharp intraday round-trip and tells traders this name still carries serious volatility.
On the daily chart, SCNI has pulled back from the $1.90–$2.00 area seen in late September toward the low $1s. The stock has managed to stay above the key $1.00 Nasdaq line, which now matters more than ever after regaining compliance. For short-term traders, that $1 area is the psychological floor to watch.
More Breaking News
- PARR Stock Stays In Focus As Analysts Reset Price Targets
- LCID Stock Slides As Q3 Miss, Legal Overhang Rattle Traders
- RXRX Stock Drifts Lower As Traders Gauge Biotech Runway
- FCHL Stock Pops On Volatile Spike As Traders Pile In
Fundamentally, Scinai Immunotherapeutics is still in build-out mode. Revenue sits near $1.31M with a price-to-sales ratio around 1.22, which is low for a speculative biotech. Book value per share is roughly $1.83, while SCNI trades below that level, hinting at a discounted balance sheet story. At the same time, returns on assets and equity are deeply negative, showing that SCNI is far from profitability. This mix sets up a classic high-risk, high-reward biotech trading profile where news, liquidity, and sentiment drive the tape.
Why Traders Are Watching SCNI After Nasdaq Compliance Win
Traders focus on clear catalysts, and SCNI just removed a big negative one. Scinai Immunotherapeutics has regained compliance with Nasdaq’s $1.00 minimum bid price rule after holding above that level for 19 consecutive trading days. Nasdaq has officially closed its non-compliance matter, which takes the immediate delisting risk off the table for SCNI.
When a small-cap biotech like Scinai Immunotherapeutics trades under delisting pressure, every downtick feels heavier. Many funds and retail traders avoid names that might get kicked off a major exchange. Now that SCNI is back in good standing, the story can shift away from survival and back toward execution.
That’s where the NanoAb immunology programs come in. Scinai Immunotherapeutics is working on these next‑generation antibody treatments while also pushing its CDMO operations. For traders, this dual track matters. The NanoAb programs are the long-term scientific upside, while CDMO services have the potential to bring steadier revenue if Scinai can win and retain contracts.
The intraday chart on 2026/10/13 tells you how the crowd is processing all this. SCNI spiked from roughly $1.13 at 07:00 to above $3.00 in premarket, then faded hard back into the $1s. That’s the kind of liquidity burst you see when a headline—like confirmed Nasdaq compliance—collides with a thin float and a day-trader heavy tape. For disciplined traders, the lesson is clear: respect the volatility, trade the levels, and let the Nasdaq overhang’s removal inform your bias, not control it.
Conclusion
With Nasdaq compliance restored, SCNI enters a new phase. Scinai Immunotherapeutics is no longer shadowed by the threat of being pushed off a major exchange, and that alone can help stabilize who is willing to trade the name and at what size. Now the spotlight returns to execution: advancing the NanoAb immunology pipeline and scaling the CDMO business.
SCNI’s numbers underline the stakes. The company holds about $11.6M in total assets and roughly $8.1M in equity, with just 31 employees driving the entire Scinai Immunotherapeutics operation. Yet returns on assets around -35% and a highly negative return on equity show how early and risky this story still is. The stock trading below book value while clinging above $1.00 sets up a battleground between value-focused biotech traders and those wary of continued losses.
For active traders, SCNI is a classroom in real time. You have a clear technical line at $1.00, a known catalyst in the Nasdaq compliance news, and a volatile chart that rewards patience and punishes chasing. As Tim Sykes likes to say, “The market doesn’t owe you anything; it only rewards preparation and discipline.” That dovetails with the process-focused approach many successful day and swing traders emphasize; as Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.”. Scinai Immunotherapeutics is now a name where that mindset matters more than ever, and any trading in SCNI should be approached as a tactical, educational exercise—not as a blind bet.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.